{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-024784","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.053608+00:00","generated_at":"2026-05-24T14:17:49.422824+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia secures up to $100M in additional financing from HCR for YUTREPIA commercialization","bullets":["$25M funded at closing; $50M contingent on first commercial sale of YUTREPIA after FDA approval for PAH/PH-ILD (no injunction).","Additional $25M available if YUTREPIA net sales exceed $100M by June 30, 2026, subject to mutual agreement.","Payments capped at 175% of amounts advanced; minimum IRR rates: 16%/13%/12% for three new tranches.","CFO: combination of proceeds and successful YUTREPIA launch could lead to profitability without additional capital.","Proceeds to fund YUTREPIA commercial development, clinical trials, L606 development, and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-024784","json":"https://secwatch.observer/filing/0001104659-25-024784.json","markdown":"https://secwatch.observer/filing/0001104659-25-024784.md","text":"https://secwatch.observer/filing/0001104659-25-024784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925024784/0001104659-25-024784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925024784/tm259465d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:17:49.422824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}